Generex Biotechnology Corp.

COVID-19 Vaccine Project

NuGenerex Immuno-Oncology, a Subsidiary of Generex Biotechnology (NGIO) has signed a development and commercial licensing agreement with partners in China to develop a vaccine against the SARS-COV-2 coronavirus. The agreement provides exclusive rights to the Ii-Key- SARS-COV-2 peptide vaccines in China; NGIO retains worldwide rights to the Ii-Key peptide vaccines.

Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines

https://www.globenewswire.com/news-release/2020/02/27/1992098/0/en/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html